Physician profile
Mary E Greene
NPI 1801152699
$1,226.24
in general payments reported to CMS, 2019-2025
14 companies · $88.27 in 2025
The $88.27 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $126 · 2022: $92.10 · 2023: $225 · 2024: $570 · 2025: $88.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $227.11 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.38 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $151.10 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.99 | 2019 | |
| Bardy Diagnostics, INC. | $113.43 | 2021 | |
| Medtronic, INC. | $83.94 | 2022-2025 | Corevalve Evolut R |
| Heartflow, INC. | $61.95 | 2022-2024 | Ffrct |
| Lexicon Pharmaceuticals, INC. | $55.45 | 2024 | |
| Amgen INC. | $52.33 | 2024-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $41.97 | 2024 | Xarelto |
| Abiomed | $38.86 | 2024 | Impella |
| Boston Scientific Corporation | $19.67 | 2023 | Watchman |
| Lilly USA, LLC | $16.79 | 2025 | Zepbound, Mounjaro |
| Pfizer INC. | $14.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.